Keep this practical
A set of clinician-confirmed prompts for people considering ibogaine: records, medication review, stabilization, travel planning, consent, and the final days before treatment.
01 / Start with the whole picture
Preparing for ibogaine begins well before travel. Use the broader preparation overview to organize questions, then ask a qualified clinician to confirm what information is needed for your individual situation. Do not withhold prescriptions, non-prescription products, supplements, recent medication changes, alcohol use, or other substance use.
Ask for a current, written medication reconciliation that includes names, doses, timing, recent changes, and why each item is used. Clinician review should explicitly consider drugs associated with QT prolongation or rhythm risk, including some antiarrhythmics, antipsychotics, antidepressants, antibiotics, antifungals, antiemetics, and methadone. The FDA’s warning about ondansetron and abnormal heart rhythms illustrates why medication-specific cardiac review matters.
Confirm which records should travel with you: a medication list, clinician notes, relevant diagnoses, allergy information, recent laboratory results, ECG findings if obtained, and emergency contacts. Ask who will review each document before any treatment decision and how updated information will be communicated if your health status changes.
02 / Stabilization is not a shortcut
Do not use a generic timeline in place of clinical assessment. Ask qualified clinicians to identify whether any abstinence, taper, transition, or stabilization period is appropriate before ibogaine, especially for opioids and other substances. The answer depends on the substance, medication history, withdrawal risk, physical health, and the plan for monitored care.
Ask exactly how opioids, alcohol, sedatives, stimulants, and other substances may affect screening, withdrawal, cardiac risk, and observation needs. Sudden changes can be dangerous; do not stop prescribed medication or attempt to manage withdrawal alone in order to meet a timeline.
Confirm who can monitor you during any clinician-directed transition period, how worsening symptoms will be handled, and when urgent or emergency care is needed. The SAMHSA National Helpline information describes routes to treatment referral support for substance-use concerns in the United States.
03 / Travel needs a safety plan
If travel is involved, confirm practical arrangements before departure rather than treating them as details to solve on arrival. Treatment outside regulated medical settings can be high risk and may be illegal. Ask qualified professionals about the laws and standards that apply where you live and where treatment is proposed.
04 / Consent must be specific
Before any decision, confirm the proposed setting, screening process, monitoring plan, emergency escalation, aftercare expectations, and the limits of what the people involved can provide. Ask how new symptoms, abnormal test results, medication changes, or a changed substance-use history would affect the plan.
Ibogaine is discussed in the context of substance use, but “natural” does not mean risk-free. The background on ibogaine notes its psychoactive nature and the need for careful consideration of safety concerns. A responsible consent discussion should not minimize uncertainty, promise an outcome, or replace independent medical advice.
Confirm the plan, the backup plan, and the point at which the plan stops being appropriate.
05 / The immediate pre-treatment period
In the days immediately before treatment, follow only the plan confirmed by qualified clinicians. Do not introduce new supplements, use non-disclosed substances, make abrupt medication changes, or treat online advice as a substitute for individualized review. Tell the responsible clinical team promptly about illness, dehydration, fainting, chest symptoms, palpitations, new prescriptions, missed medication, or changed substance use.
It should cover every prescription, over-the-counter medicine, supplement, recent dose change, and substance use disclosure. Ask specifically how cardiac history and potentially QT-prolonging medicines are being evaluated, and whether further clinical assessment is needed before any travel or treatment decision.
Confirm supervised observation, a viable emergency transport plan, access to documentation, practical support after treatment, and the legal context of the destination. For a concise framework on the questions this resource emphasizes, see the preparation topics covered by Prebogaine Preparation.
Accurate disclosure gives clinicians the information needed to assess interactions, withdrawal risk, and whether a proposed plan should change. Hiding a recent use pattern or medication change can make screening less meaningful and emergency planning less reliable.
Pause when screening is incomplete, key questions remain unanswered, emergency arrangements are unclear, or you are being pressured to proceed. The risk and monitoring considerations offer additional prompts for reviewing whether safeguards are concrete rather than assumed.
Use it to prepare a complete conversation with qualified clinicians, preserve your records, and identify gaps before travel or treatment. For independent background on ibogaine and addiction considerations, ibogaine anti-addiction information can be read alongside clinician-confirmed guidance—not in place of it.